Updated efficacy and safety of oral erdafitinib in patients with bacillus calmette-guérin–unresponsive, high-risk non-muscle–invasive bladder cancer with fgfr3/2 alterations in thor-2 cohort 2

Urologic Oncology: Seminars and Original Investigations(2024)

引用 0|浏览2
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要